01276.HK
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 46.26
+4.14%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenHKD 45.20
From 52W high−50.84%
Volume5.92M
Market capHKD 307.04B
P/E (TTM)35.0x
P/S (TTM)—
Div yield0.49%
Key dataSep 18, 2026
Open
HKD 45.20
From 52W high
−50.84%
Volume
5.92M
Market cap
HKD 307.04B
ValuationView details →
P/E (Fwd)
29.3x
EV/EBITDA
—
P/E (TTM)
35.0x
RSI (14)
44.6
MomentumView details →
1D Return
+4.14%
YTD Return
−35.21%
Similar companies
Latest newsMore news →
Hengrui Pharmaceuticals reported R&D spending of 4.605 billion yuan in the first half of 2026, up 18.96% year on year and equal to 29.8% of revenue.6h agoHengrui Pharmaceuticals reported that in the first half of 2026 its innovative-drug sales revenue rose to 8.809 billion yuan, 63.16% of drug sales revenue, with non-oncology innovative-drug revenue up 73.97%.6h agoHengrui Pharmaceuticals received Chinese approval in 2026 for four Class 1 innovative drugs — rilafusp alfa injection, luzonorestat sodium tablets, insulin sudi injection and fumurate likangcopan capsules — plus the Class 2 new drug cyclosporine eye drops (IV).6h ago